NeuroPace (NASDAQ:NPCE) Downgraded by JPMorgan Chase & Co. to Neutral

NeuroPace (NASDAQ:NPCE) was downgraded by research analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a report issued on Friday, MarketBeat Ratings reports. They presently have a $9.00 price objective on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential downside of 25.12% from the stock’s previous close.

Several other research firms have also recently weighed in on NPCE. Guggenheim restated a “neutral” rating on shares of NeuroPace in a report on Wednesday, July 29th. Raymond James Financial set a $21.00 price objective on shares of NeuroPace in a research note on Tuesday, September 15th. Mizuho assumed coverage on shares of NeuroPace in a research note on Thursday, July 23rd. They issued an “outperform” rating and a $22.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of NeuroPace in a research report on Wednesday, July 29th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NeuroPace in a research note on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.00.

NeuroPace Stock Performance

NASDAQ NPCE opened at $12.02 on Friday. NeuroPace has a 1 year low of $11.90 and a 1 year high of $19.60. The company has a debt-to-equity ratio of 4.97, a current ratio of 4.94 and a quick ratio of 3.91. The firm has a market cap of $412.53 million, a price-to-earnings ratio of -21.09 and a beta of 1.98. The company has a fifty day moving average price of $13.35 and a 200-day moving average price of $14.79.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. NeuroPace had a negative net margin of 19.34% and a negative return on equity of 105.64%. The company had revenue of $22.83 million during the quarter, compared to the consensus estimate of $22.61 million. As a group, equities research analysts predict that NeuroPace will post -0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

Large investors have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of NeuroPace during the 2nd quarter worth $39,369,000. GSA Capital Partners LLP purchased a new position in shares of NeuroPace in the 2nd quarter worth about $1,836,000. First Light Asset Management LLC boosted its holdings in shares of NeuroPace by 16.3% in the 2nd quarter. First Light Asset Management LLC now owns 2,861,167 shares of the company’s stock worth $45,464,000 after buying an additional 401,201 shares during the last quarter. Deutsche Bank AG bought a new position in NeuroPace during the second quarter valued at about $14,919,000. Finally, Man Group plc bought a new position in NeuroPace during the second quarter valued at about $1,336,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

More NeuroPace News

These are some of the NPCE news items that stood out recently:

• Positive Sentiment: NeuroPace reported a quarterly loss of $0.03 per share, narrower than the $0.11 loss analysts expected and the $0.11 loss a year earlier. Zacks article
• Negative Sentiment: Revenue was $23.1 million, below analysts’ $27.12 million expectation. RNS System revenue was $22.9 million, up just 1.4% year over year, pointing to limited growth. NeuroPace earnings release
• Negative Sentiment: The company lowered its 2026 revenue outlook to $91 million–$92 million, well below the roughly $100.4 million analyst consensus. The guidance reduction, alongside the quarterly revenue miss, is the clearest near-term negative catalyst for NPCE shares. Coverage of NeuroPace’s reduced guidance

About NeuroPace

NeuroPace, Inc. is a medical technology company focused on treating people with drug-resistant epilepsy. Its primary product is the RNS System, an implanted responsive neurostimulation device designed to detect patterns of abnormal electrical activity in the brain and deliver stimulation in response. The RNS System includes a neurostimulator implanted in the skull and leads placed in or near seizure-onset areas of the brain. Clinicians use the system to review brain activity and adjust treatment, while patients can use accompanying tools to record information about their seizures and share it with their care team.